HRP20170075T1 - Spoj benzotiazolona - Google Patents
Spoj benzotiazolona Download PDFInfo
- Publication number
- HRP20170075T1 HRP20170075T1 HRP20170075TT HRP20170075T HRP20170075T1 HR P20170075 T1 HRP20170075 T1 HR P20170075T1 HR P20170075T T HRP20170075T T HR P20170075TT HR P20170075 T HRP20170075 T HR P20170075T HR P20170075 T1 HRP20170075 T1 HR P20170075T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- acceptable salt
- pharmaceutically acceptable
- free form
- image
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011079379 | 2011-09-06 | ||
| EP12770249.6A EP2753609B1 (en) | 2011-09-06 | 2012-09-05 | Benzothiazolone compound |
| PCT/IB2012/054580 WO2013035047A1 (en) | 2011-09-06 | 2012-09-05 | Benzothiazolone compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170075T1 true HRP20170075T1 (hr) | 2017-03-24 |
Family
ID=47010668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170075TT HRP20170075T1 (hr) | 2011-09-06 | 2012-09-05 | Spoj benzotiazolona |
Country Status (39)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| HUE033655T2 (en) * | 2012-08-30 | 2017-12-28 | Novartis Ag | Benzothiazolone Compounds with Beta-2-Adrenoceptor Effects |
| EP2920176B1 (en) | 2012-11-19 | 2017-09-13 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines as mknk1 kinase inhibitors |
| SI2961391T1 (sl) * | 2013-02-28 | 2017-08-31 | Novartis Ag | Formulacija,ki obsega benzotiazolonsko spojino |
| US10967119B1 (en) | 2019-04-01 | 2021-04-06 | Azizi Bilal | Wearable medication injecting device |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0662324A1 (en) * | 1987-09-15 | 1995-07-12 | The Rowett Research Institute | Use of beta-adrenergic agonists for treating loss of function of striated muscles |
| US20070082918A1 (en) * | 1993-11-02 | 2007-04-12 | Naftchi N E | Neurologically active compounds and compounds with multiple activities |
| GB9405019D0 (en) | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
| ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| WO1999009018A1 (en) | 1997-08-14 | 1999-02-25 | Kirin Beer Kabushiki Kaisha | BENZOTHIAZOLONE DERIVATIVES HAVING SELECTIVE β2 RECEPTOR AGONIST ACTIVITY |
| AU760250B2 (en) | 1998-12-04 | 2003-05-08 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US6872723B2 (en) * | 2002-01-28 | 2005-03-29 | Wyeth | Stabilized difloxacin injectable solution |
| US6743797B2 (en) * | 2002-02-22 | 2004-06-01 | Chantest, Inc. | Methods for treating cardiac arrhythmia |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AR040962A1 (es) * | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| BRPI0408680A (pt) * | 2003-03-26 | 2006-03-28 | Pharmacia & Upjohn Co Llc | processo para produzir álcoois e aminas enantiomericamente enriquecidos |
| CA2521271C (en) * | 2003-04-04 | 2011-01-04 | Novartis Ag | Quinoline-2-one-derivatives for the treatment of airways diseases |
| BRPI0411275A (pt) | 2003-06-10 | 2006-08-01 | Kalypsys Inc | compostos de carbonila como inibidores de histona deacetilase para tratamento de doenças; composição farmacêutica; método de modular a atividade catalìtica de hdac; método de tratar doença em um indivìduo; utilização de um composto ou composição; método de inibir hdac |
| JP2007503472A (ja) * | 2003-06-10 | 2007-02-22 | カリプシス・インコーポレーテッド | 病気治療用のヒストン脱アセチル化酵素阻害剤としてのカルボニル化合物 |
| EP1646370A1 (en) | 2003-07-11 | 2006-04-19 | Glaxo Group Limited | Pharmaceutical formulations |
| JP2009513531A (ja) | 2003-07-11 | 2009-04-02 | グラクソ グループ リミテッド | 糖エステルを含む吸入可能医薬製剤 |
| ES2329586T3 (es) | 2003-11-21 | 2009-11-27 | Theravance, Inc. | Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino. |
| GB0328490D0 (en) | 2003-12-09 | 2004-01-14 | Glaxo Group Ltd | Medicinal compounds |
| JP2005187357A (ja) | 2003-12-25 | 2005-07-14 | Nippon Suisan Kaisha Ltd | 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法 |
| GB0402797D0 (en) | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
| EP1595873A1 (de) | 2004-05-13 | 2005-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen |
| WO2005110990A1 (de) | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen |
| EP1778638A1 (en) | 2004-07-21 | 2007-05-02 | Theravance, Inc. | Diaryl ether beta2 adrenergic receptor agonists |
| DE102004045648A1 (de) | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| GB0426164D0 (en) * | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| DE102005007654A1 (de) | 2005-02-19 | 2006-08-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
| TW200740781A (en) | 2005-08-29 | 2007-11-01 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| WO2007086078A2 (en) | 2006-01-30 | 2007-08-02 | Panacea Biotec Ltd. | Novel pharmaceutical compositions and process of preparation thereof |
| EP1986633B1 (en) | 2006-02-10 | 2014-07-30 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| TW200745084A (en) | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| GB0613154D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| MX2009001534A (es) * | 2006-08-10 | 2009-04-08 | Us Gov Health & Human Serv | Preparacion de (r,r)-fenoterol y analogos de (r,r)- o (r,s)-fenoterol y su uso en el tratamiento de insuficiencia cardiaca congestiva. |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| LT2170396T (lt) | 2007-08-03 | 2017-03-10 | Summit (Oxford) Limited | Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| GB0814728D0 (en) | 2008-08-12 | 2008-09-17 | Argenta Discovery Ltd | New combination |
| GB0823140D0 (en) | 2008-12-18 | 2009-01-28 | Astrazeneca Ab | New combination |
| GB201009801D0 (en) | 2010-06-11 | 2010-07-21 | Astrazeneca Ab | Compounds 950 |
| GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| HUE033655T2 (en) * | 2012-08-30 | 2017-12-28 | Novartis Ag | Benzothiazolone Compounds with Beta-2-Adrenoceptor Effects |
| SI2961391T1 (sl) | 2013-02-28 | 2017-08-31 | Novartis Ag | Formulacija,ki obsega benzotiazolonsko spojino |
-
2012
- 2012-09-04 JO JOP/2012/0250A patent/JO3192B1/ar active
- 2012-09-05 SG SG2014013114A patent/SG2014013114A/en unknown
- 2012-09-05 ES ES12770249.6T patent/ES2615052T3/es active Active
- 2012-09-05 AP AP2014007462A patent/AP3830A/en active
- 2012-09-05 DK DK12770249.6T patent/DK2753609T3/en active
- 2012-09-05 EA EA201490573A patent/EA022909B1/ru not_active IP Right Cessation
- 2012-09-05 UA UAA201401193A patent/UA114295C2/uk unknown
- 2012-09-05 MY MYPI2014000358A patent/MY163301A/en unknown
- 2012-09-05 CN CN201280043386.3A patent/CN103781771B/zh not_active Expired - Fee Related
- 2012-09-05 EP EP12770249.6A patent/EP2753609B1/en active Active
- 2012-09-05 TW TW101132414A patent/TWI555738B/zh not_active IP Right Cessation
- 2012-09-05 SI SI201230841A patent/SI2753609T1/sl unknown
- 2012-09-05 PL PL12770249T patent/PL2753609T3/pl unknown
- 2012-09-05 CN CN201610536836.2A patent/CN106187942B/zh not_active Expired - Fee Related
- 2012-09-05 US US13/603,990 patent/US8933108B2/en not_active Expired - Fee Related
- 2012-09-05 RS RS20161145A patent/RS55468B1/sr unknown
- 2012-09-05 HU HUE12770249A patent/HUE030530T2/en unknown
- 2012-09-05 CU CUP2014000028A patent/CU24303B1/xx unknown
- 2012-09-05 WO PCT/IB2012/054580 patent/WO2013035047A1/en not_active Ceased
- 2012-09-05 UY UY0001034312A patent/UY34312A/es not_active Application Discontinuation
- 2012-09-05 KR KR1020167007782A patent/KR101800140B1/ko not_active Expired - Fee Related
- 2012-09-05 PH PH1/2014/500399A patent/PH12014500399A1/en unknown
- 2012-09-05 BR BR112014004732A patent/BR112014004732A2/pt not_active Application Discontinuation
- 2012-09-05 CA CA2845766A patent/CA2845766A1/en not_active Abandoned
- 2012-09-05 HR HRP20170075TT patent/HRP20170075T1/hr unknown
- 2012-09-05 PT PT127702496T patent/PT2753609T/pt unknown
- 2012-09-05 KR KR1020147008777A patent/KR101628585B1/ko not_active Expired - Fee Related
- 2012-09-05 AU AU2013200422A patent/AU2013200422C1/en not_active Ceased
- 2012-09-05 LT LTEP12770249.6T patent/LT2753609T/lt unknown
- 2012-09-05 PE PE2014000312A patent/PE20141993A1/es not_active Application Discontinuation
- 2012-09-05 MX MX2014002688A patent/MX345405B/es active IP Right Grant
- 2012-09-05 JP JP2014529113A patent/JP6130835B2/ja not_active Expired - Fee Related
- 2012-09-06 AR ARP120103276A patent/AR087787A1/es unknown
-
2014
- 2014-02-10 TN TNP2014000060A patent/TN2014000060A1/en unknown
- 2014-02-13 ZA ZA2014/01112A patent/ZA201401112B/en unknown
- 2014-02-27 IL IL231235A patent/IL231235A/en active IP Right Grant
- 2014-02-27 CL CL2014000493A patent/CL2014000493A1/es unknown
- 2014-03-04 GT GT201400042A patent/GT201400042A/es unknown
- 2014-03-06 CR CR20140114A patent/CR20140114A/es unknown
- 2014-03-06 CO CO14048375A patent/CO6900147A2/es not_active Application Discontinuation
- 2014-12-10 US US14/566,021 patent/US20150094346A1/en not_active Abandoned
-
2015
- 2015-02-03 ZA ZA2015/00790A patent/ZA201500790B/en unknown
- 2015-08-03 US US14/817,175 patent/US20150336914A1/en not_active Abandoned
- 2015-11-20 US US14/947,458 patent/US20160075670A1/en not_active Abandoned
-
2016
- 2016-06-10 US US15/178,579 patent/US9913828B2/en active Active
-
2017
- 2017-02-02 CY CY20171100153T patent/CY1118585T1/el unknown
- 2017-03-01 JP JP2017038701A patent/JP6340103B2/ja not_active Expired - Fee Related
-
2018
- 2018-01-22 US US15/876,619 patent/US10251868B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170075T1 (hr) | Spoj benzotiazolona | |
| ME02321B (me) | Antivirusna jedinjenja | |
| EP2650293A8 (en) | [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof | |
| GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
| BR112015020545A2 (pt) | derivado de tetraidroimidazo[1,5-d][1,4]oxazepina | |
| BR112013030894A2 (pt) | moduladores do sistema imune | |
| FI4159217T3 (fi) | Mek-estäjän ja b-raf-estäjän käsittävä yhdistelmä | |
| AR084824A1 (es) | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas | |
| IN2014KN00948A (enExample) | ||
| EP2639229A3 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
| EP2590655A4 (en) | COMPOUNDS AND METHOD FOR INHIBITING PHOSPHATE TRANSPORT | |
| WO2008147557A3 (en) | Heteroaryl substituted thiazoles and their use as antiviral agents | |
| UA99447C2 (ru) | Способ получения силденафила | |
| ME02576B (me) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| SI2945620T1 (en) | Nitroxyl donors with improved therapeutic index | |
| HRP20130959T1 (hr) | Antikancerozni spojevi i farmaceutski pripravci koji ih sadrže | |
| FI3119911T3 (fi) | Yhdisteitä käytettäväksi alzheimerin taudin hoitamisessa apoe4+/+-potilaissa | |
| WO2011097946A8 (zh) | 含有并环稠合双环的噁唑烷酮化合物及其制备和应用 | |
| CA2873096A1 (en) | Compositions and methods for the treatment of inflammatory bowel disease | |
| JP2017132781A5 (enExample) | ||
| MX2014002480A (es) | Uso del compuesto organico para el tratamiento del sindrome de noonan. | |
| FR2939667B1 (fr) | Composition d'immunoglobine g comme medicament pour le traitement de l'ictere neonatal par incompatibilite foetomaternelle dans le systeme abo | |
| ME02351B (me) | Derivati 2 -oxo- 1-imidazolidinil imidazotiadiazol | |
| JP2016512541A5 (enExample) | ||
| JP2013522207A5 (enExample) |